GREENLAND MINES LTD Professional Fees
GREENLAND MINES LTD (GRML) reported Professional Fees of $3.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2026-08-17
- GREENLAND MINES LTD professional fees for the quarter ending 2026-06-30 was $3.95M, a 327.48% increase year-over-year.
- GREENLAND MINES LTD professional fees for the quarter ending 2026-03-31 was $2.98M, a 304.34% increase year-over-year.
- GREENLAND MINES LTD professional fees for the quarter ending 2025-12-31 was $1.06M, a 5.60% decline year-over-year.
- GREENLAND MINES LTD professional fees for the quarter ending 2025-09-30 was $711.17K, a 17.87% decline year-over-year.
- GREENLAND MINES LTD professional fees for fiscal 2025 was $3.44M, a 24.43% increase from fiscal 2024.
- GREENLAND MINES LTD professional fees for fiscal 2024 was $2.76M, a 359.61% increase from fiscal 2023.
- GREENLAND MINES LTD professional fees for fiscal 2023 was $600.78K.
| Period end | Professional Fees 3 month | Professional Fees 3 month as first filed | Professional Fees 6 month | Professional Fees 6 month as first filed | Professional Fees 9 month | Professional Fees 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3.95M 10-Q · filed 2026-08-17 | $6.93M 10-Q · filed 2026-08-17 | $7.99M derived: sum of 3 quarters · filed 2026-08-17 | $8.71M derived: sum of 4 quarters · filed 2026-08-17 | ||
| 2026-03-31 | $2.98M 10-Q/A · filed 2026-08-14 | $4.04M derived: sum of 2 quarters · filed 2026-08-14 | $4.75M derived: sum of 3 quarters · filed 2026-08-14 | $5.68M derived: sum of 4 quarters · filed 2026-08-17 | ||
| 2025-12-31 | $1.06M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $1.77M derived: sum of 2 quarters · filed 2026-08-14 | $2.70M derived: sum of 3 quarters · filed 2026-08-17 | $3.44M 10-K/A · filed 2026-08-14 | ||
| 2025-09-30 | $711.17K 10-Q · filed 2025-11-13 | $1.64M derived: sum of 2 quarters · filed 2026-08-17 | $2.37M 10-Q · filed 2025-11-13 | $3.50M derived: sum of 4 quarters · filed 2026-08-17 | ||
| 2025-06-30 | $924.58K 10-Q · filed 2026-08-17 | $1.66M 10-Q · filed 2026-08-17 | $2.79M derived: sum of 3 quarters · filed 2026-08-17 | $3.65M derived: sum of 4 quarters · filed 2026-08-17 | ||
| 2025-03-31 | $736.69K 10-Q/A · filed 2026-08-14 | $1.86M derived: sum of 2 quarters · filed 2026-08-14 | $2.73M derived: sum of 3 quarters · filed 2026-08-14 | $3.08M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2024-12-31 | $1.13M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $1.99M derived: sum of 2 quarters · filed 2026-08-14 | $2.35M derived: sum of 3 quarters · filed 2026-08-14 | $2.76M 10-K/A · filed 2026-08-14 | ||
| 2024-09-30 | $865.93K 10-Q · filed 2025-11-13 | $1.22M derived: sum of 2 quarters · filed 2025-11-13 | $1.63M 10-Q · filed 2025-11-13 | $1.70M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $355.75K 10-Q · filed 2025-08-18 | $393.27K 10-Q · filed 2024-08-19 | $731.35K 10-Q · filed 2025-08-18 | $768.86K 10-Q · filed 2024-08-19 | $838.05K derived: sum of 3 quarters · filed 2025-08-18 | $955.82K derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | $375.60K 10-Q · filed 2025-05-15 | $482.30K derived: sum of 2 quarters · filed 2025-05-15 | $600.07K derived: sum of 3 quarters · filed 2025-05-15 | $829.10K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $106.70K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $224.47K derived: sum of 2 quarters · filed 2025-03-31 | $453.51K derived: sum of 3 quarters · filed 2025-03-31 | $600.78K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $117.77K 10-Q · filed 2024-11-19 | $346.81K derived: sum of 2 quarters · filed 2024-11-19 | $494.07K 10-Q · filed 2024-11-19 | |||
| 2023-06-30 | $229.03K 10-Q · filed 2024-08-19 | $376.31K 10-Q · filed 2024-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |